AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00886704 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 500 mg eicosapentaenoic (EPA) plus docosahexaenoic acids (DHA)
Description: Composition of active convenience drink (smartfish): 200 ml drink, enriched with 940 mg omega-3 fatty acids, of which 200 mg are EPA, 300 mg DHA and 100 mg DPA, slightly carbonized..~Energy content 486 kJ (116 kcal), protein 0.6 g, Carbohydrates 22 g, total fat 4 g, of which 0.6 g saturated fatty acids, 1.8 g monounsaturates, 1.4 g polyunsaturates. Vitamin D 0.85 ug.~Control convenience drink: as above, containing about 1 g Omega-6 fatty acids from e.g. corn oil.
Study NCT00886704 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: 500 mg eicosapentaenoic (EPA) plus docosahexaenoic acids (DHA)
Description: Composition of active convenience drink (smartfish): 200 ml drink, enriched with 940 mg omega-3 fatty acids, of which 200 mg are EPA, 300 mg DHA and 100 mg DPA, slightly carbonized..~Energy content 486 kJ (116 kcal), protein 0.6 g, Carbohydrates 22 g, total fat 4 g, of which 0.6 g saturated fatty acids, 1.8 g monounsaturates, 1.4 g polyunsaturates. Vitamin D 0.85 ug.~Control convenience drink: as above, containing about 1 g Omega-6 fatty acids from e.g. corn oil.
Study NCT00886704 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control convenience drink
Description: Control convenience drink: as above, containing about 1 g Omega-6 fatty acids from e.g. corn oil.
Study NCT01068197 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Low Glycemic Load Diet versus Low Fat Diet
Description: We propose a randomized controlled clinical trial to evaluate the effectiveness of a low-glycemic load diet versus low-fat diet on insulin sensitivity, body composition, and other hormonal and biochemical measures. The culturally competent and family-based Intervention program has a dietary experimental component (low-glycemic load versus low-fat diet), as well as elements of physical activity, reduction in sedentary behavior and behavior modification. The nutrition training sessions are divided into 12 modules taught over a 12-week course. Care has been taken to make the content and intensity of the low-fat and low-glycemic load programs comparable. Both treatments include 12 weekly sessions, followed by nine monthly, and four 3-monthly sessions.~Participants are obese (BMI ≥95th percentile for age and sex) Hispanic American children ages 7-14 years.
Study NCT01068197 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low Glycemic Load Diet versus Low Fat Diet
Description: We propose a randomized controlled clinical trial to evaluate the effectiveness of a low-glycemic load diet versus low-fat diet on insulin sensitivity, body composition, and other hormonal and biochemical measures. The culturally competent and family-based Intervention program has a dietary experimental component (low-glycemic load versus low-fat diet), as well as elements of physical activity, reduction in sedentary behavior and behavior modification. The nutrition training sessions are divided into 12 modules taught over a 12-week course. Care has been taken to make the content and intensity of the low-fat and low-glycemic load programs comparable. Both treatments include 12 weekly sessions, followed by nine monthly, and four 3-monthly sessions.~Participants are obese (BMI ≥95th percentile for age and sex) Hispanic American children ages 7-14 years.
Study NCT02256605 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Vitamin D-3
Description: Children with IBD, aged 5 to 17, who are vitamin D insufficient or deficient will be recruited at the time of a routine clinic visit or lab draw that included a 25(OH)D level as part of clinical practice/standard care. Once consent and assent are obtained, the children who are 25-hydroxyvitamin D \[259OH)D\] insufficient or deficient will be randomly assigned to a daily or weekly dosing regimen using block randomization to ensure equal group size.
Study NCT04541290 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Protopic 0.1 % Topical Ointment
Description: Applied in a thin layer covering all of the arm including the armpit and hand once a day for six months
Study NCT01033526 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin (Acetylsalicylic acid, BAYE4465)
Description: 1-2 tablets Acetylsalicylic Acid 400 mg (in combination with Ascorbic Acid 240 mg) as needed every 4-6 hours over a maximum of 5 days
Study NCT01033526 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1-2 tablets matching Placebo as needed every 4-6 hours over a maximum of 5 days
Study NCT00350584 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Telehealth Intervention
Description: Two in-person sessions and six telephone sessions with a therapist. Focus is on learning mindfulness skills.
Study NCT00350584 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducation Telehealth Intervention
Description: Two in-person sessions and six telephone sessions with a therapist. Focus is on education about PTSD.
Study NCT01022996 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus (RAD001)
Description: Everolimus (RAD001) 10 mg (two 5mg tablets) given orally once daily and packed in blisters.
Study NCT03975270 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab and Nab-paclitaxel
Description: Sintilimab in Combination with Nab-paclitaxel in Patients with Advanced Recurrent or Metastatic HNSCC after 2 or More Prior Lines of Therapy
Study NCT00998049 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: plerixafor
Description: Plerixafor 160mg/kg/dose by IV on days 5-8
Study NCT00998049 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Filgrastim (G-CSF) 10 mg/kg/dose subcutaneously on days 1-8.
Study NCT02728661 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PACE
Description: PACE is an 14 week behavioral weight loss intervention developed specifically for knee replacement patients that starts up to 6 weeks prior to surgery.
Study NCT02728661 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Delayed PACE
Description: Delayed PACE is an 14 week behavioral weight loss intervention developed specifically for knee replacement patients that starts 12 weeks after surgery.
Study NCT03433495 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Melodic Intonation Therapy
Study NCT03228303 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nilotinib 150 MG [Tasigna]
Description: Nilotinib vs imatinib in patients with newly diagnosed CML-CP
Study NCT03228303 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imatinib 400mg
Description: Nilotinib vs imatinib in patients with newly diagnosed CML-CP
Study NCT05187052 — intervention group
Intervention type: OTHER
Intervention: Tracheal intubation
Description: Video-assisted intubation technique
Study NCT02018406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination injection of EPO and G-CSF
Description: Subcutaneous EPO(300 U/kg)+G-CSF(10 μg/kg) injection once a day, 5 times a cycle (a week), total 3 cycles for 3 months.
Study NCT02018406 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Injection of normal saline
Description: Subcutaneous normal saline injection once a day, 5 times a cycle (a week), total 3 cycles for 3 months.
Study NCT03887845 — intervention group
Intervention type: PROCEDURE
Intervention: Surgery
Description: The respective surgical approach for any gastric and colorectal surgery
Study NCT02251379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flovent Diskus
Description: Inhaled corticosteroids
Study NCT02251379 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flovent Diskus
Description: Inhaled corticosteroids
Study NCT02251379 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home Environmental Intervention
Description: Mouse, Cockroach, Furry pets, Dust mites, Smoking, air purifiers, laundered bedding
Study NCT02251379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Advair Diskus
Description: inhaled corticosteroids + long-acting beta agonist
Study NCT02251379 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Advair Diskus
Description: inhaled corticosteroids + long-acting beta agonist
Study NCT02518451 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan 160 mg film-coated caplets (test formulation)
Description: In each of the two study periods (separated by a washout of one week) a single dose of test or reference formulation was administered.
Study NCT02518451 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valsartan 160 mg film-coated caplets (reference formulation)
Description: In each of the two study periods (separated by a washout of one week) a single dose of test or reference formulation was administered.
Study NCT02982369 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spinal Manipulation
Description: High-velocity and low-amplitude (HVLA) manipulation techniques to the cervical and thoracic region
Study NCT02982369 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Pain Education
Description: Subjects will receive pain education based in biopsychosocial approach
Study NCT02982369 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pain Education
Description: Subjects will receive pain education based in biopsychosocial approach
Study NCT02982369 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: A simulation of spinal manipulation (sham), involving manual contact over the cervical and thoracic region totaling 10 minutes.
Study NCT05092178 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: calorie restricted diet and exercise
Description: The CR diet and exercise group received a balanced diet with an energy consists carbohydrates 45-65%; fat 20-35%; and protein 10- 35% and a deficit of 600 kcal/day from their daily energy requirement.The exercise intervention consists of aerobic exercises and resistance exercise, flexibility exercises about 150 minutes for≥2 d•wk for six months. The aerobic exercises included walking on a treadmill, stationary cycling for at least 30 minutes for≥2 d•wk, while, resistance exercises included nine upper-extremity and lower-extremity exercise with weighting lift machines for ≥2 d•wk, while, flexibility exercise including the major muscle-tendon groups (a total of 60 s per exercise) for ≥2 d•wk. Participants performed 1 or 2 sets with 8-12 repetitions of each exercise. The exercise sessions were monitored by telephone video.
Study NCT05092178 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: exercise alone
Description: In exercise alone group, participants then underwent their usual habitual dietary diet and the above exercise intervention during the program.
Study NCT03066908 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sinopsys® Lacrimal Stent
Description: Transcaruncular paranasal sinus or nasal cavity access for the purpose of irrigating the ethmoid sinus with saline
Study NCT01753583 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optical Coherence Tomography (OCT)
Description: High-resolution OCT imaging of the cornea
Study NCT01753583 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Slit lamp biomicroscopy
Description: Slit lamp biomicroscopy with fluorescein staining and slit lamp photograph
Study NCT04332224 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blanketrol cooling device and water-perfused blankets
Description: Blanketrol and water-perfused blankets
Study NCT04332224 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blanketrol and Kool Kit
Description: Blanketrol cooling device with water-perfused vest, hood and lower body blanket
Study NCT04332224 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Arctic Sun
Description: Arctic Sun cooling device with gel cooling pads
Study NCT03385720 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: modified neck dissection
Description: Modified neck dissection with preservation of submandibular gland. The submandibular gland is preserved during neck dissection.
Study NCT03385720 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: traditional neck dissection
Description: traditional neck dissection without preservation of submandibular gland
Study NCT04346498 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chest-to-back
Study NCT04346498 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Chest-to-back
Study NCT03305289 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: pulsed Radiofrequency
Description: sensory stimulation will be carried out at 50 Hz. The definitive position of the electrode will be verified by inducing paresthesia with sensory stimulation between 0.1-0.3 V in the affected painful area, then pulsed radiofrequency will be applied for 10 patients for 10 mins
Study NCT03305289 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: thermal Radiofrequency
Description: sensory stimulation will be carried out at 50 Hz. The definitive position of the electrode will be verified by inducing paresthesia with sensory stimulation between 0.1-0.3 V in the affected painful area, then Thermal lesion will be applied for 10 patients for 2 cycles of 90 seconds
Study NCT01540825 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 113608
Description: Low dose powder for oral solution
Study NCT01540825 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 113608
Description: High dose powder for oral solution
Study NCT01540825 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 113608
Description: Medium dose powder for oral solution
Study NCT01540825 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Powder for oral solution
Study NCT03511534 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychotherapy
Description: Evidenced based psychotherapy by a trained psychologist
Study NCT03511534 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pharmacotherapy
Description: Pharmacotherapy by a psychiatrist
Study NCT00709111 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc
Description: The maraviroc doses were 150 mg orally twice daily, 300 mg orally twice daily, or 600 mg orally twice daily, depending on the pharmacokinetic interaction with a subject's pre-study ART and non-ART drug regimen according to the package insert.
Study NCT02398448 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zyloprim® 300 mg
Study NCT02398448 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allopurinol 300 mg; undergranulated, high hardness condition
Description: There will be a period for interim analysis after administration of Regimen B to determine the formulation within the process design space that provides the desired in vitro dissolution variant for dosing in the subsequent study period
Study NCT02398448 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allopurinol 300 mg; alternative condition 2
Description: There will be a period for interim analysis after administration of Regimen C to determine the formulation within the process design space that provides the desired in vitro dissolution variant for dosing in the subsequent study period
Study NCT02398448 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allopurinol 300 mg; alternative condition 3
Study NCT05109286 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CrossFit
Description: CrossFit training
Study NCT01580865 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus vs. Mycophenolate mofetil for Induction Therapy in Lupus Nephritis
Description: Patients were randomly assigned to receive regimen I or II: TAC plus prednisolone (TAC group) or MMF plus prednisolone (MMF group). TAC was started at a dosage of 0.1 mg/kg/day divided into 2 daily doses at 12-hour intervals, and the dosage was titrated to achieve trough blood concentrations of 6-10 ng/mL in the first and second month and then 4-8 ng/mL., thereafter. MMF was initiated at a dose of 500 mg twice daily (for patients > 50 Kg and Estimated Glomerular Filtration rate (eGFR) > 60 ml/min) for 2 weeks, and advanced to 750 mg twice daily in LN patients weighing less than 50 kg or 1,000 mg twice daily in LN patients weighing 50 kg or more. Patients received concomitant prednisone at a dose of 0.5-0.7 mg/kg/d (maximum 60 mg/day), with tapering by 5-10 mg/day every 2 weeks until a dose of 5 mg/d has been achieved, and this dosage was maintained until the end of 24 weeks.
Study NCT01580865 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus vs. Mycophenolate mofetil for Induction Therapy in Lupus Nephritis
Description: Patients were randomly assigned to receive regimen I or II: TAC plus prednisolone (TAC group) or MMF plus prednisolone (MMF group). TAC was started at a dosage of 0.1 mg/kg/day divided into 2 daily doses at 12-hour intervals, and the dosage was titrated to achieve trough blood concentrations of 6-10 ng/mL in the first and second month and then 4-8 ng/mL., thereafter. MMF was initiated at a dose of 500 mg twice daily (for patients > 50 Kg and Estimated Glomerular Filtration rate (eGFR) > 60 ml/min) for 2 weeks, and advanced to 750 mg twice daily in LN patients weighing less than 50 kg or 1,000 mg twice daily in LN patients weighing 50 kg or more. Patients received concomitant prednisone at a dose of 0.5-0.7 mg/kg/d (maximum 60 mg/day), with tapering by 5-10 mg/day every 2 weeks until a dose of 5 mg/d has been achieved, and this dosage was maintained until the end of 24 weeks.
Study NCT02438891 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy
Description: Cognitive behavioral therapy is a form of tinnitus psychotherapy which aims to help patients control negative thoughts or emotions associated with tinnitus.
Study NCT04012034 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiofrequency A
Description: Application of radiofrequency for 30 minutes per week during 8 weeks
Study NCT04012034 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Radiofrequency B
Description: Application of radiofrequency without energy for 30 minutes per week during 8 weeks
Study NCT03203499 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ANS-6637 Oral Tablet
Description: Ascending single doses administered orally.
Study NCT03203499 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo administered orally.
Study NCT02267603 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Ancillary studies
Study NCT02267603 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study NCT03100799 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Arthroscopy
Description: Arthroscopy of the target knee
Study NCT03100799 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Arthrocentesis
Description: Arthrocentesis of the target knee and contralateral knee (if patient consents)
Study NCT03100799 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: MRI
Description: MRI with and without a gadolinium-based contrast agent
Study NCT03319407 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: EPAD monitoring system
Description: EPAD system will be used as part of routine care
Study NCT00943709 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: insulin glargine recombinant
Description: Given subcutaneously
Study NCT00943709 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: insulin glargine recombinant
Description: Given subcutaneously
Study NCT00943709 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: therapeutic insulin
Description: Given subcutaneously
Study NCT00943709 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: therapeutic insulin
Description: Given subcutaneously
Study NCT03794583 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled treprostinil solution
Description: Inhaled treprostinil solution per dose and schedule specified in the arm
Study NCT02851420 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: spectroscopy
Study NCT02851420 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: spectroscopy
Study NCT04179747 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Psychotherapy
Description: The Cognitive Behavior Psychotherapy was provided for a period of maximum 3 months.
Study NCT04179747 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil Citrate 50Mg Tab
Description: The participants in control group arm received Sildenafil Citrate 50mg tablet on demand for a period of maximum 3 months.
Study NCT01509079 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Cholecalciferol capsule, 4000IU, daily for 6 months
Study NCT01509079 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: cholecalciferol capsule, 600 IU, daily for 6 months
Study NCT04595253 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acupressure
Description: The acupressure involves the  Vaccaria Semen within skin-colored adhesive tape that placed on the Neiguan and Shenmen acupoints as an intervention measure. Continue to massage the acupoints with fingertips for 10 minutes, 3 times per day (8 and 12 in the morning, and 4 in the afternoon) . The adhesive tape will be retained in situ for 2 days.